| 1 (58) | Samsung Corp * | MUL |  |
| 2 (93) | Bristol-Myers Squibb Company * | MUL | |
| 3 (95) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA | |
| 4 (100) | Genentech Inc | USA | |
| 5 (102) | AstraZeneca * | MUL | |
| 6 (103) | Sanofi, United States | USA | |
| 7 (109) | F Hoffmann-La Roche * | MUL | |
| 8 (111) | Hoffmann-La Roche Ltd, United States | USA | |
| 9 (115) | GlaxoSmithKline * | MUL | |
| 10 (160) | Bristol-Myers Squibb Company, United States | USA | |
| 11 (181) | AstraZeneca, United States | USA | |
| 12 (203) | Boehringer Ingelheim * | MUL | |
| 13 (210) | GlaxoSmithKline, United States | USA | |
| 14 (223) | Merck & Co Inc * | MUL | |
| 15 (228) | Eli Lilly * | MUL | |
| 16 (237) | Sanofi * | MUL | |
| 17 (248) | Merck & Co Inc, United States | USA | |
| 18 (249) | Bayer * | MUL | |
| 19 (250) | Boehringer Ingelheim GmbH Germany | DEU | |
| 20 (290) | Eli Lilly and Company, United States | USA | |
| 21 (297) | GlaxoSmithKline, United Kingdom | GBR | |
| 22 (310) | Regeneron Pharmaceuticals Inc * | USA | |
| 23 (323) | Novartis * | MUL | |
| 24 (340) | AstraZeneca, Sweden | SWE | |
| 25 (399) | Pfizer * | MUL | |
| 26 (459) | AstraZeneca, United Kingdom | GBR | |
| 27 (489) | Bayer AG, Germany | DEU | |
| 28 (537) | Sanofi, France | FRA | |
| 29 (572) | Analysis Group Inc | USA | |
| 30 (639) | Robert Bosch * | MUL | |
| 31 (662) | Novartis, Switzerland | CHE | |
| 32 (762) | Boehringer Ingelheim, USA | USA | |
| 33 (791) | Johnson & Johnson * | MUL | |
| 34 (818) | Janssen | MUL | |
| 35 (833) | Bosch, Germany | DEU | |
| 36 (1012) | IQVIA Inc * | MUL | |
| 37 (1233) | UnitedHealth Group * | MUL | |
| 38 (1272) | Takeda Pharmaceuticals International Inc * | MUL | |
| 39 (1352) | Takeda Pharmaceuticals International Inc, USA | USA | |
| 40 (1365) | Pharmaceutical Product Development LLC | USA | |
|
